Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences
  • Register
  • Login

Urology Journal

  • Home
  • Instant Online
    • Instant 2023
    • Instant 2022
    • Instant 2021
    • Instant 2020
  • Current
  • Archives
  • Announcements
  • Submissions
  • Author Guidelines
  • About
    • About the Journal
    • Privacy Statement
    • Contact
Advanced Search
  1. Home
  2. Archives
  3. Vol. 20 No. 01 (2023): January-February 2023
  4. ORIGINAL PAPER(UROLOGICAL ONCOLOGY)

ISSN: 1735-1308

January-February 2023
Vol. 20 No. 01 (2023)

Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers

  • Fatih Gokalp
  • Serdar Celik
  • Tevfik Sinan Sozen
  • Abdurrahim Haluk Ozen
  • Guven Aslan
  • Volkan Izol
  • Sumer Baltaci
  • Talha Muezzinoglu
  • Bulent Akdogan
  • Evren Suer
  • Ilker Tinay

Urology Journal, Vol. 20 No. 01 (2023), , Page 29-33
https://doi.org/10.22037/uj.v19i.7091 Published 25 December 2022

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Purpose: We aimed to compare oncological outcomes in the two rare subtypes, unclassified renal cell cancer (unRCC) and translocation RCC (tRCC), vs clear cell RCC (ccRCC).
Materials and Methods: Between 2004 and 2019, from Turkish Urooncology Society Database, we identified 2324 patients for histological subtypes including 80 unRCC (3.4%), 19 tRCC (0.8%) and 2225 ccRCC (95.8%).
Results: The overall (15.8%) and cancer-specific mortalities (11.1%) were found to be higher in tRCC group and the recurrence free mortality (13.8%) was found to be higher in unRCC group. Larger pathological tumor size (p = 0.012) and advanced pathological T stage (p = 0.042) were independent predictive factors on overall mortality in patients with unRCC tumors.
Conclusion: The oncological outcomes of the unRCC and tRCC are worse than ccRCC and pathological tumor size and pathological stage are predictive factors for mortality in the unRCC.

Keywords:
  • Kidney, kidney cancer, oncology, pathology
  • 7091/pdf

How to Cite

Gokalp, F., Celik, S., Sozen, T. S., Ozen, A. H., Aslan, G., Izol, V., Baltaci, S., Muezzinoglu, T., Akdogan, B., Suer, E., & Tinay, I. (2022). Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers. Urology Journal, 20(01), 29-33. https://doi.org/10.22037/uj.v19i.7091
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

Zisman A, Chao DH, Pantuck AJ, et al. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol. 2002;168:950-5.

Karakiewicz PI, Hutterer GC, Trinh QD, et al. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int. 2007;100:802-8.

Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-91.

Sirohi D, Smith SC, Agarwal N, Maughan BL. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Res Rep Urol. 2018;10:205.

Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31:1149-60.

Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet. 2016;387:2008-16.

Armah HB, Parwani AV. Xp11.2 translocation renal cell carcinoma. Arch Pathol Lab Med. 2010;134:124-9. doi:10.5858/2008-0391-RSR.1

Hu ZY, Pang LJ, Qi Y, et al. Unclassified renal cell carcinoma: a clinicopathological, comparative genomic hybridization, and whole-genome exon sequencing study. Int J Clin Exp Pathol. 2014;7:3865.

Chen YB, Xu J, Skanderup AJ, et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun. 2016;7:1-10.

Perrino CM, Grignon DJ, Williamson SR, Idrees MT, Eble JN, Cheng L. Morphological spectrum of renal cell carcinoma, unclassified: an analysis of 136 cases. Histopathology. 2018;72:305-19.

Crispen PL, Tabidian MR, Allmer C, et al. Unclassified renal cell carcinoma: impact on survival following nephrectomy. Urology. 2010;76:580-6.

Çelik S, Altay C, Değer MD, et al. Postoperative and Mid-term Outcomes of Unclassified Renal Cell Carcinoma. Uroonkoloji Buelteni Bull Urooncology. 2021;20:117.

Ellis CL, Eble JN, Subhawong AP, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Mod Pathol. 2014;27:875-86.

Caliò A, Segala D, Munari E, Brunelli M, Martignoni G. MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge. Cancers. 2019;11:1110.

Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32:656-70.

  • Abstract Viewed: 0 times
  • 7091/pdf Downloaded: 0 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

In case of persistent problems in registration, primary uploading of a submission or uploading of a revision, please send us the submission files on the journal email at:

urologyjournal@sbmu.ac.ir

and please attach the screenshot of the error or problem you encountered in uploading.

 

Make a Submission

          Journal Research in Urology

Information
  • For Readers
  • For Authors
Keywords
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact
The template of this website is designed by Sinaweb